Nektar Announces Key Executive Promotions to Drive the Continued Growth of the Company's Immuno-Oncology Pipeline Wed, 22 Nov 2017 21:15:00 +0000 Jonathan Zalevsky, Ph.D., has been promoted to Senior Vice President, Research and Chief Scientific Officer. "I am exceptionally pleased to announce today's promotions which highlight the talent, skill set and extensive achievements of our executive team," said Howard W. Robin, President and CEO of Nektar Therapeutics.
With Latest Update, FDA Approval Soon Could Send BTCY Ripping Mon, 20 Nov 2017 12:30:00 +0000 Response to US FDA Request Met, BTCY Could be Right Around the Corner From an FDA Clearance by Year-End, Likelihood of Approval is High Unexpected News Can Send Stocks--Especially Biomedical Stocks--Flying ...
3 Biotech Stocks to Be Thankful for This Year Sun, 19 Nov 2017 16:43:00 +0000 If you notice a relative who can't stop grinning at the Thanksgiving dinner table, they're probably holding shares of these biotech stocks.
3 Biotech Stocks That Soared: Are They Buys? Sat, 18 Nov 2017 22:47:00 +0000 Could Nektar Therapeutics, Wave Life Sciences, and Savara go even higher after huge gains this past week?
What’s Next for Nektar Therapeutics? Sat, 18 Nov 2017 17:40:00 +0000 This midcap biotech stock is flying higher and given how many drugs are in its pipeline, it could only be getting started.
*Winners defined as our Top Picks that increased 20% or more within a 6-month period.
Red Letters imply that that particular criteria did not meet minimum requirements, e.g., a low GSA Rank would show it in red.
___ Red Line On Graph Shows a Trailing Stop Loss Based on Support and Resistance Levels. See how it works.
___ Blue Line On Graph Shows the 10-Week Moving Average.
___ Magenta Line On Graph Shows the 40-Week Moving Average.
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.